Prelude Therapeutics (PRLD) Accounts Payables (2019 - 2026)

Prelude Therapeutics (PRLD) has 8 years of Accounts Payables data on file, last reported at $2.1 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables fell 64.52% year-over-year to $2.1 million; the trailing twelve-month figure through Mar 2026 stood at $2.1 million (down 64.52% YoY), and the FY2025 full-year result was $4.0 million, down 48.49% from the prior year.
• Accounts Payables eased to $2.1 million in Q1 2026, from $4.0 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $10.2 million in Q3 2022 to a low of $2.1 million in Q1 2026.
• A 5-year average of $5.7 million and a median of $5.8 million in 2025 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables soared 68.82% in 2024 and plunged 64.52% in 2026, its largest moves.
• Tracing PRLD's Accounts Payables over 5 years: stood at $6.8 million in 2022, then slumped by 32.42% to $4.6 million in 2023, then jumped by 68.82% to $7.7 million in 2024, then slumped by 48.49% to $4.0 million in 2025, then sank by 48.05% to $2.1 million in 2026.
• Business Quant data shows PRLD's Accounts Payables at $2.1 million in Q1 2026, $4.0 million in Q4 2025, and $2.5 million in Q3 2025.